Higher TILs expression at pre-treatment compared to post-treatment was seen across all BC subgroups with consistent results in studies reported TILs as categorical or continuous variable types, with a more distinct decreasing trend seen in HER2-positive subgroup. This evidence concerns the gene ERBB2 and breast cancer.